Drug Type Small molecule drug |
Synonyms T3BDPFL |
Target |
Action inhibitors |
Mechanism RIPK1 inhibitors(Receptor-interacting serine/threonine-protein kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alzheimer Disease | Preclinical | United States | 10 May 2024 | |
| Autoimmune Diseases | Preclinical | United States | 10 May 2024 | |
| Inflammation | Preclinical | United States | 10 May 2024 | |
| Neoplasms | Preclinical | United States | 10 May 2024 |





